NATURAL KILLER T CELL LIGAND LOADED EXTRACELLULAR NANOVESICLE AND AUTOLOGOUS ANTI-CANCER VACCINE FOR HEMATOLOGIC MALIGNANCIES COMPRISING THE SAME
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 13, 2024
app pub date -
Dec 4, 2023
filing date -
Dec 8, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides a natural killer T cell ligand-loaded extracellular nanovesicle, and an autologous anticancer vaccine for hematologic malignancies including the above extracellular nanovesicle. More particularly, a cancer cell-derived extracellular nanovesicle in which a natural killer T cell ligand as an adjuvant is bound to a surface thereof, and an autologous anticancer vaccine including the same, which can recognize cancer antigens specific to patients with hematologic malignancies and has cancer cell-specific anticancer function thus to enable T cell activation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully